HC Wainwright Issues Optimistic Estimate for CareDx Earnings

CareDx, Inc (NASDAQ:CDNA) – Analysts at HC Wainwright increased their Q2 2025 earnings estimates for CareDx in a report issued on Monday, May 5th. HC Wainwright analyst Y. Chen now expects that the company will post earnings of ($0.09) per share for the quarter, up from their previous forecast of ($0.15). HC Wainwright has a “Neutral” rating and a $25.00 price target on the stock. The consensus estimate for CareDx’s current full-year earnings is ($0.90) per share. HC Wainwright also issued estimates for CareDx’s Q3 2025 earnings at ($0.05) EPS, Q4 2025 earnings at $0.00 EPS, FY2025 earnings at ($0.33) EPS, Q1 2026 earnings at ($0.03) EPS, Q2 2026 earnings at $0.04 EPS, Q3 2026 earnings at $0.09 EPS, Q4 2026 earnings at $0.16 EPS and FY2026 earnings at $0.26 EPS.

CDNA has been the topic of several other reports. Wells Fargo & Company raised shares of CareDx from an “underweight” rating to an “equal weight” rating and cut their target price for the stock from $28.00 to $24.00 in a research note on Wednesday, January 15th. Stephens restated an “overweight” rating and issued a $40.00 target price on shares of CareDx in a research note on Monday, May 5th. StockNews.com downgraded CareDx from a “buy” rating to a “hold” rating in a research note on Monday, May 5th. Finally, The Goldman Sachs Group reduced their price objective on CareDx from $34.00 to $26.00 and set a “buy” rating for the company in a research note on Thursday, April 17th. Four analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat, CareDx has a consensus rating of “Moderate Buy” and an average target price of $30.33.

CareDx Stock Performance

CareDx stock opened at $15.42 on Thursday. The stock has a market capitalization of $858.60 million, a price-to-earnings ratio of -5.71 and a beta of 2.27. CareDx has a 52-week low of $12.53 and a 52-week high of $34.84. The stock’s 50 day moving average price is $17.87 and its two-hundred day moving average price is $21.16.

CareDx (NASDAQ:CDNA) last announced its quarterly earnings data on Wednesday, April 30th. The company reported $0.09 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.06 by $0.03. CareDx had a negative return on equity of 53.70% and a negative net margin of 45.90%. The company had revenue of $84.69 million for the quarter, compared to the consensus estimate of $84.56 million. During the same period in the previous year, the business earned ($0.03) EPS. The firm’s revenue was up 17.6% compared to the same quarter last year.

Hedge Funds Weigh In On CareDx

Institutional investors have recently modified their holdings of the business. Divisadero Street Capital Management LP purchased a new position in CareDx in the fourth quarter worth $15,239,000. Chevy Chase Trust Holdings LLC bought a new stake in shares of CareDx during the 1st quarter worth $9,502,000. Jacobs Levy Equity Management Inc. boosted its holdings in shares of CareDx by 52.6% in the 4th quarter. Jacobs Levy Equity Management Inc. now owns 1,243,580 shares of the company’s stock worth $26,625,000 after buying an additional 428,864 shares during the last quarter. Bamco Inc. NY grew its position in CareDx by 17.6% during the fourth quarter. Bamco Inc. NY now owns 2,207,299 shares of the company’s stock valued at $47,258,000 after buying an additional 330,627 shares during the period. Finally, Vanguard Group Inc. increased its holdings in CareDx by 7.1% during the fourth quarter. Vanguard Group Inc. now owns 4,859,732 shares of the company’s stock worth $104,047,000 after buying an additional 323,554 shares during the last quarter.

Insiders Place Their Bets

In related news, Director Christine Cournoyer sold 16,700 shares of the business’s stock in a transaction dated Tuesday, May 6th. The shares were sold at an average price of $14.13, for a total transaction of $235,971.00. Following the transaction, the director now directly owns 37,045 shares in the company, valued at approximately $523,445.85. The trade was a 31.07 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Peter Maag sold 13,281 shares of CareDx stock in a transaction that occurred on Wednesday, April 30th. The stock was sold at an average price of $17.23, for a total transaction of $228,831.63. Following the transaction, the director now directly owns 316,743 shares in the company, valued at approximately $5,457,481.89. This represents a 4.02 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 30,246 shares of company stock valued at $469,498. Corporate insiders own 4.90% of the company’s stock.

CareDx Company Profile

CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.